{"id":68698,"date":"2026-06-22T21:43:22","date_gmt":"2026-06-22T13:43:22","guid":{"rendered":"https:\/\/flcube.com\/?p=68698"},"modified":"2026-06-22T21:43:23","modified_gmt":"2026-06-22T13:43:23","slug":"curegene-pharmaceutical-initiates-pivotal-us-clinical-trial-for-evategrel-worlds-first-dual-formulation-p2y12-inhibitor-addressing-clopidogrel-resistance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68698","title":{"rendered":"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World&#8217;s First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai CureGene Pharmaceutical Co., Ltd.<\/strong> announced the enrollment of the first patient in a <strong>pivotal regulatory clinical study<\/strong> for <strong>evategrel (CG-0255)<\/strong> in the <strong>United States<\/strong>, marking a significant milestone for its <strong>globally first-in-class next-generation antiplatelet agent<\/strong>. Evategrel represents the <strong>world&#8217;s first P2Y12 receptor inhibitor<\/strong> available in both <strong>intravenous and oral formulations<\/strong>, featuring an innovative mechanism that bypasses hepatic CYP450 metabolism to address the critical clinical challenge of <strong>&#8220;clopidogrel resistance&#8221;<\/strong> affecting nearly <strong>60% of East Asian patients<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-development-milestone-amp-clinical-strategy\" class=\"wp-block-heading\">Development Milestone &amp; Clinical Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Pivotal regulatory clinical trial<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>United States<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Cardiovascular disease patients requiring antiplatelet therapy<\/td><\/tr><tr><td><strong>Molecule Status<\/strong><\/td><td>Globally first-in-class P2Y12 inhibitor<\/td><\/tr><tr><td><strong>Formulations<\/strong><\/td><td>Intravenous and oral (dual administration options)<\/td><\/tr><tr><td><strong>Primary Innovation<\/strong><\/td><td>CYP450-independent metabolic activation pathway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-mechanism-of-action-amp-clinical-advantages\" class=\"wp-block-heading\">Mechanism of Action &amp; Clinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Thiol-Hydrolyzing Prodrug Design:<\/strong> Metabolically activated by <strong>carboxylesterases<\/strong> widely distributed throughout the human body<\/li>\n\n\n\n<li><strong>CYP450 Bypass:<\/strong> Completely avoids hepatic <strong>CYP2C19-dependent pathway<\/strong>, eliminating genetic polymorphism-related efficacy issues<\/li>\n\n\n\n<li><strong>Addresses Clopidogrel Resistance:<\/strong> Solves the fundamental problem affecting <strong>60% of East Asian population<\/strong> with reduced CYP2C19 enzyme activity<\/li>\n\n\n\n<li><strong>Enhanced Pharmacokinetics:<\/strong><\/li>\n\n\n\n<li><strong>Rapid onset of action<\/strong> compared to traditional thienopyridines<\/li>\n\n\n\n<li><strong>Minimal inter-individual variability<\/strong> in drug response<\/li>\n\n\n\n<li><strong>Reduced drug-drug interaction risks<\/strong> due to non-CYP450 metabolism<\/li>\n\n\n\n<li><strong>Dual Administration Flexibility:<\/strong> IV formulation for acute settings, oral for chronic maintenance therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-significance\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Antiplatelet Market:<\/strong> Valued at <strong>US$8.5 billion annually<\/strong>, with P2Y12 inhibitors representing the largest segment<\/li>\n\n\n\n<li><strong>Clopidogrel Limitations:<\/strong> Despite widespread use, <strong>30-60% of patients<\/strong> exhibit suboptimal response due to genetic and metabolic factors<\/li>\n\n\n\n<li><strong>Asian Market Priority:<\/strong> Particularly transformative for East Asian populations where clopidogrel resistance prevalence is highest<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Superior to existing P2Y12 inhibitors (prasugrel, ticagrelor) that still face limitations in onset speed, bleeding risk, or drug interactions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-development-strategy\" class=\"wp-block-heading\">Global Development Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The initiation of US pivotal trials demonstrates CureGene&#8217;s commitment to <strong>global regulatory standards<\/strong> and positions evategrel for potential approval in both Western and Asian markets. The dual-formulation approach addresses unmet needs across the entire cardiovascular care continuum\u2014from acute coronary syndrome management to long-term secondary prevention.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view this as a potential <strong>paradigm shift<\/strong> in antiplatelet therapy, with evategrel&#8217;s innovative metabolic pathway offering consistent efficacy regardless of patient genetics, comorbidities, or concomitant medications. Successful clinical validation could establish CureGene as a major player in the global cardiovascular therapeutics market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai CureGene Pharmaceutical Co., Ltd. announced the enrollment of the first patient in a pivotal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1575],"class_list":["post-68698","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-curegene-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World&#039;s First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd. announced the enrollment of the first patient in a pivotal regulatory clinical study for evategrel (CG-0255) in the United States, marking a significant milestone for its globally first-in-class next-generation antiplatelet agent. Evategrel represents the world&#039;s first P2Y12 receptor inhibitor available in both intravenous and oral formulations, featuring an innovative mechanism that bypasses hepatic CYP450 metabolism to address the critical clinical challenge of &quot;clopidogrel resistance&quot; affecting nearly 60% of East Asian patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68698\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World&#039;s First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance\" \/>\n<meta property=\"og:description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd. announced the enrollment of the first patient in a pivotal regulatory clinical study for evategrel (CG-0255) in the United States, marking a significant milestone for its globally first-in-class next-generation antiplatelet agent. Evategrel represents the world&#039;s first P2Y12 receptor inhibitor available in both intravenous and oral formulations, featuring an innovative mechanism that bypasses hepatic CYP450 metabolism to address the critical clinical challenge of &quot;clopidogrel resistance&quot; affecting nearly 60% of East Asian patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68698\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T13:43:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T13:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68698#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68698\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World&#8217;s First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance\",\"datePublished\":\"2026-06-22T13:43:22+00:00\",\"dateModified\":\"2026-06-22T13:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68698\"},\"wordCount\":433,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CureGene Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68698#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68698\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68698\",\"name\":\"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World's First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-22T13:43:22+00:00\",\"dateModified\":\"2026-06-22T13:43:23+00:00\",\"description\":\"Shanghai CureGene Pharmaceutical Co., Ltd. announced the enrollment of the first patient in a pivotal regulatory clinical study for evategrel (CG-0255) in the United States, marking a significant milestone for its globally first-in-class next-generation antiplatelet agent. Evategrel represents the world's first P2Y12 receptor inhibitor available in both intravenous and oral formulations, featuring an innovative mechanism that bypasses hepatic CYP450 metabolism to address the critical clinical challenge of \\\"clopidogrel resistance\\\" affecting nearly 60% of East Asian patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68698#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68698\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68698#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World&#8217;s First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World's First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced the enrollment of the first patient in a pivotal regulatory clinical study for evategrel (CG-0255) in the United States, marking a significant milestone for its globally first-in-class next-generation antiplatelet agent. Evategrel represents the world's first P2Y12 receptor inhibitor available in both intravenous and oral formulations, featuring an innovative mechanism that bypasses hepatic CYP450 metabolism to address the critical clinical challenge of \"clopidogrel resistance\" affecting nearly 60% of East Asian patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68698","og_locale":"en_US","og_type":"article","og_title":"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World's First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance","og_description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced the enrollment of the first patient in a pivotal regulatory clinical study for evategrel (CG-0255) in the United States, marking a significant milestone for its globally first-in-class next-generation antiplatelet agent. Evategrel represents the world's first P2Y12 receptor inhibitor available in both intravenous and oral formulations, featuring an innovative mechanism that bypasses hepatic CYP450 metabolism to address the critical clinical challenge of \"clopidogrel resistance\" affecting nearly 60% of East Asian patients.","og_url":"https:\/\/flcube.com\/?p=68698","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-22T13:43:22+00:00","article_modified_time":"2026-06-22T13:43:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68698#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68698"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World&#8217;s First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance","datePublished":"2026-06-22T13:43:22+00:00","dateModified":"2026-06-22T13:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68698"},"wordCount":433,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CureGene Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68698#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68698","url":"https:\/\/flcube.com\/?p=68698","name":"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World's First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-22T13:43:22+00:00","dateModified":"2026-06-22T13:43:23+00:00","description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced the enrollment of the first patient in a pivotal regulatory clinical study for evategrel (CG-0255) in the United States, marking a significant milestone for its globally first-in-class next-generation antiplatelet agent. Evategrel represents the world's first P2Y12 receptor inhibitor available in both intravenous and oral formulations, featuring an innovative mechanism that bypasses hepatic CYP450 metabolism to address the critical clinical challenge of \"clopidogrel resistance\" affecting nearly 60% of East Asian patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68698#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68698"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68698#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CureGene Pharmaceutical Initiates Pivotal US Clinical Trial for Evategrel, World&#8217;s First Dual-Formulation P2Y12 Inhibitor Addressing Clopidogrel Resistance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68698"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68698\/revisions"}],"predecessor-version":[{"id":68699,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68698\/revisions\/68699"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}